Renaming NAFLD to MAFLD: Advantages and Potential Changes in Diagnosis, Pathophysiology, Treatment, and Management-Reference-Cited by-同舟云学术

Renaming NAFLD to MAFLD: Advantages and Potential Changes in Diagnosis, Pathophysiology, Treatment, and Management

Published:2022-05-03 Issue:2 Volume:4 Page:49-55
ISSN:2641-5917
Container-title:Infectious Microbes and Diseases
language:en
Short-container-title:

Author:

Rui Fajuan,Yang Hongli,Hu Xinyu,Xue Qi,Xu Yayun,Shi Junping,Li Jie

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference87 articles.

1. The evaluation of drug delivery nanocarrier development and pharmacological briefing for metabolic-associated fatty liver disease (MAFLD): an update;Abou Assi;Pharmaceuticals (Basel),2021

2. Role of insulin resistance in MAFLD;Sakurai;Int J Mol Sci,2021

3. What's in a name? Renaming ’NAFLD’ to ’MAFLD’;Fouad;Liver Int,2020

4. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy;Xian;Chin Med J (Engl),2020

5. From NAFLD to MAFLD: implications of a premature change in terminology;Younossi;Hepatology,2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mitochondrial dysfunction: A promising therapeutic target for liver diseases;Genes & Diseases;2024-05

2. Test All for Hepatitis B Virus;Clinics in Liver Disease;2023-11

3. Case Report of Metabolic Dysfunction-Associated Fatty Liver Disease Treated with <italic>Saenggangunbi-tang</italic>;The Journal of Internal Korean Medicine;2023-05-31

4. Association of Diabetes Mellitus with All-Cause and Cause-Specific Mortality among Patients with Metabolic-Dysfunction-Associated Fatty Liver Disease: A Longitudinal Cohort Study;Journal of Personalized Medicine;2023-03-20

5. Valuing the Prevention and Treatment of Liver Disease to Promote Human Wellbeing;Infectious Microbes and Diseases;2022-05-17